特拉唑嗪对帕金森病患者运动功能改善情况的临床观察  

Efficacy observation of terazosin in the movement disorder improvement of Parkinson's disease

作　　者：吴林[1] 臧静 刘娟[1] 杨芳[1] 孔凡斌[1] Wu Lin;Zang Jing;Liu Juan;Yang Fang;Kong Fanbin(Department of Neurology,People's Hospital of Rizhao,Shandong,Rizhao,Shandong,276800,China)

机构地区：[1]山东省日照市人民医院神经内科,山东日照276800

出　　处：《当代医学》2020年第36期110-112,共3页Contemporary Medicine

基　　金：济宁医学院青年教师科研扶持基金(JY2017FS024)。

摘　　要：目的通过观察服用特拉唑嗪的帕金森病患者运动症状变化,探讨特拉唑嗪在疾病进展过程中的保护作用。方法选取2017年12月至2019年1月日照市人民医院门诊及病房50例男性PD患者,按照随机数字表法分为观察组与对照组,各25例。分别进行帕金森综合评分量表(UPDRS-Ⅲ)评分,观察组给予原方案加特拉唑嗪2 mg(睡前),对照组原方案加安慰剂治疗,连续3月后,比较两组评分。结果观察组PD患者UPDRS-Ⅲ评分明显低于对照组(P<0.05)。结论服用特拉唑嗪能延缓PD患者运动症状的进展。Objective To explore the clinical efficacy of Terazosin in the improvement of Parkinson's disease movement and investigate the protection to the disease.Methods 50 male patients with Parkinson's disease were randomly divided into the test group and the control group,with 25 cases in each group.The test group was added with terazosin 2 mg(before bed)and the control group was added with placebo.The unified Parkinson's disease rating scale(UPDRS-Ⅲ)were compared and analyzed before and after treatment in two groups after 3 months.Results Compared with the control group,the scale of UPDRSⅢof test group decreased after treatment.Conclusion Terazosin can improve the progress of the movement symptoms of Parkinson's disease.

关 键 词：帕金森病 特拉唑嗪 运动症状 

分 类 号：R742.5[医药卫生—神经病学与精神病学]